"randomised, multicentre, double-blind, placebo-controlled study of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)"

drug protocol number
AMB115811
drug sponsor
GSK
drug study
Ambrisentan 5 mg
drug trial site
KFMC
drug status
Completed
drug phase